- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02111187
A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer (LDE225)
A Pharmacodynamic Pre-surgical Study of Hedgehog Pathway Inhibition With LDE225 in Men With High-risk Localized Prostate Cancer.
This trial is designed as a randomized two-arm (LDE225 vs. observation groups) open-label prospective clinical trial in men with localized high-risk prostate cancer undergoing radical prostatectomy.
The investigators propose to determine the effects of LDE225 on neoplastic prostate tissue from men at high risk of systemic disease progression, by comparing pre-surgical core-biopsy specimens to tumor tissue harvested at the time of prostatectomy.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide written informed consent prior to any screening procedures.
- Age 18 years or older.
- Histologically-documented prostatic adenocarcinoma in ≥2 cores
- ECOG performance status ≤2
Localized prostate cancer with at least one of the following NCCN high-risk features:
- Gleason sum ≥8
- PSA >20 ng/mL
- Clinical stage ≥T3
- Must be a candidate for radical prostatectomy
- No evidence of known metastatic disease (M0 or Mx allowed)
Adequate bone marrow, liver and renal function as specified below:
- Absolute neutrophil count (ANC) ≥ 1500/µL
- Hemoglobin (Hgb) ≥ 9.0 g/dL
- Platelets ≥100,000/µL
- Serum total bilirubin ≤ 1.5 x ULN (upper limit of normal)
- AST and ALT ≤ 2.5 x ULN
- Plasma creatine phosphokinase (CK) < 1.5 x ULN, if known
- Serum creatinine ≤ 1.5 x ULN [or 24-hour creatinine clearance ≥ 50ml/min]
- Patient is able to swallow and retain oral medications
Exclusion Criteria:
- Patients who have had major surgery within 4 weeks of enrollment.
- Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study.
- Patients unable to take oral drugs (e.g. lack of physical integrity of the upper GI tract or known malabsorption syndromes).
- Patients who have previously been treated with LDE225 or other Hh pathway inhibitors
- Patients who have neuromuscular or muscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are known to cause rhabdomyolysis (such as statins and fibrates), and that cannot be discontinued at least 2 weeks prior to starting LDE225. If it is essential that the patient stays on a statin for hyperlipidemia, only pravastatin may be used with extra caution. Patients should not plan to embark on a new strenuous exercise regimen after initiation of study treatment. (NB: Muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on LDE225 treatment).
- Patients who have taken part in an experimental drug study within 4 weeks or 5 half-lives (whichever is longer) of initiating treatment with LDE225.
- Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within 2 weeks of starting LDE225.
- Patients taking moderate/strong inhibitors or inducers of CYP3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have narrow therapeutic index, and that cannot be discontinued before starting treatment with LDE225. Medications that are strong CYP3A4/5 inhibitors should be discontinued for at least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting treatment with LDE225.
- No concurrent use of statins (except for pravastatin, if absolutely necessary)
- No concurrent warfarin or Coumadin-derivatives
Impaired cardiac function or significant heart disease, including any one of the following:
- Angina pectoris within 3 months
- Acute myocardial infarction within 3 months
- QTc >450 msec on the screening ECG
- A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome
- Other clinically significant heart disease (e.g. heart failure, uncontrolled/labile hypertension, or history of poor compliance with an antihypertensive regimen)
Patients who are not willing to apply highly effective contraception during the study and through the duration of LDE225 treatment.
- Male patients must use highly effective (double barrier) methods of contraception (e.g., spermicidal gel plus condom) for the entire duration of the study, and continuing using contraception and refrain from fathering a child for 6 months following the last dose of the study drug. A condom is also required to be used by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the study treatment via seminal fluid. Sexually active males must be willing to use a condom during intercourse while taking the study drug and for 6 months after stopping investigational medications and agree not to father a child during this period.
- Patients unwilling or unable to comply with the research protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: LDE225 (Arm1)
Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
|
Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy
Other Names:
|
No Intervention: Observation Arm (Arm2)
Observation Arm (Arm2) will receive no treatment prior to prostatectomy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation)
Time Frame: Up to 3 Years
|
This was defined as the number of patients who achieved at least a two-fold reduction in GLI1 expression in post-treatment vs. pre-treatment tumor tissues.
|
Up to 3 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With a Pathological Effect of Presurgical Treatment With LDE225
Time Frame: Up to 3 years
|
To determine whether presurgical treatment with LDE225 can exert a pathological effect on high-risk tumors (i.e. increase apoptosis, decrease proliferation).
|
Up to 3 years
|
Effect of LDE225 on PSA Recurrence Following Prostatectomy
Time Frame: Up to 3 years
|
To evaluate whether presurgical treatment with LDE225 diminishes the risk of PSA recurrence following prostatectomy.
|
Up to 3 years
|
Number of Participants With Adverse Events in Each Group (LDE225 and Observation)
Time Frame: Up to 3 years
|
Safety and tolerability, including any drug-related toxicities of Sonidegib, were reported via CTCAE version 4.0.
|
Up to 3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Emmanuel Antonarakis, M.D., Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- J1402
- NA_00091602 (Other Identifier: JHMIRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on LDE225
-
Anne ChangNovartisCompletedBasal Cell CarcinomaUnited States
-
Novartis PharmaceuticalsCompletedTreatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome PatientsAustria, Switzerland
-
University of UtahWithdrawnPancreatic Ductal AdenocarcinomaUnited States
-
Novartis PharmaceuticalsCompletedNormal Hepatic Function | Impaired Hepatic FunctionBelgium, Germany, Israel, Bulgaria, United States
-
Massachusetts General HospitalNovartisTerminatedGraft Versus Host DiseaseUnited States
-
Novartis PharmaceuticalsCompletedMedulloblastoma | Basal Cell Carcinoma | Advanced Solid Tumor CancersSpain, Switzerland, United Kingdom, United States
-
Novartis PharmaceuticalsCompletedMedulloblastoma | Basal Cell Carcinoma | Advanced Solid Tumor CancersTaiwan, Hong Kong, Japan
-
Sun Pharmaceutical Industries LimitedActive, not recruitingBasal Cell CarcinomaSpain, Germany, Italy, Switzerland
-
Novartis PharmaceuticalsCompletedNevoid Basal Cell Carcinoma Syndrome | Basal Cell Carcinoma | Gorlin SyndromeBelgium, Austria, Germany, Canada
-
Novartis PharmaceuticalsCompletedBasal Cell CarcinomaFrance, Italy, Germany, Hungary, United Kingdom, United States, Spain, Belgium, Switzerland, Australia, Canada, Greece